Philips introduces Virtual Care Management – News

A comprehensive program with a flexible fit

The highly configurable Philips Virtual Care Management solution offers health systems, providers, payers and employer groups the unique ability to customize their program in a way that shapes and scales with their evolving needs. Philips’ legacy of clinical expertise brings a clearly defined, comprehensive approach to an otherwise fragmented virtual care market by working alongside customers to help them centralize and customize their Philips Virtual Care Management program, optimize workflow and improve outcomes.

On Tuesday, March 28 at 12:00 CT, Nick Wilson will showcase Philips Virtual Care Management on the Tech Talks stage at ViVE 2023 in Nashville during a brief session entitled “Unlock the power of human-centered care, virtually anywhere.” To learn more about Philips’ extensive portfolio of ambulatory virtual care solutions, visit Philips booth #1404 at ViVE or philips.com/virtualcaremanagement.

Philips Virtual Care Management is not currently available outside the USA.

[1] Magee MF, Baker KM, Fernandez SJ, et al. Redesigning ambulatory care management for uncontrolled type 2 diabetes: a prospective cohort study of the impact of a Boot Camp model on outcomes. BMJ Open Diabetes Res Care. 2019;7(1):e000731. Published 2019 Nov 13. doi:10.1136/bmjdrc-2019-000731.
[2] A Diabetes Care Management Program for uncontrolled type 2 diabetes in a predominantly African American population amortized over the study cohort due to reduced risk of all factors hospitalization after 90 days compared to usual care.
[3] Remote patient monitoring system market size, share and trends analysis report by product (vital sign monitors, specialized monitors), by end use, by application, and segment forecasts, 2022-2030. Grand View Research. Accessed November 16, 2022. https://www.grandviewresearch.com/industry-analysis/remote-patient-monitoring-devices-market.
[4] Following a 90-day diabetes care management program in 366 subjects with type 2 diabetes, average baseline HbA1c: 11.2%.
[5] 30 day incidence risk ratio = Intervention (0.21, 95%CI 0.07 to 0.60; p=0.003) vs control (1.14, 95%CI 0.47 to 2.75; p=0.77); between group (p=0.02). 90 day IIR = intervention (0.23, 95%CI 0.11 to 0.50, p<0.001) vs. control (1.58, 95%CI 0.750 to 3.33; p=0.23); between group (P<0.001).